<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213612</url>
  </required_header>
  <id_info>
    <org_study_id>CV-1-19</org_study_id>
    <nct_id>NCT04213612</nct_id>
  </id_info>
  <brief_title>DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors</brief_title>
  <official_title>Phase I Study of Pegylated Liposomal Doxorubicin Combined With Cyclophosphamide and Vincristine in Treatment Progress, Relapse, and Refractory Solid Tumors in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doxorubicin is an anthracycline antibiotic that is part of the standard treatment for many
      pediatric malignancies, but its long-term cardiotoxicity cannot be ignored. Without affecting
      overall survival, in order to improve the quality of life of childhood tumor survivors and
      reduce cardiotoxicity, drugs with less cardiotoxicity should be selected; compared with
      ordinary doxorubicin, PEGylated doxorubicin (PLD ) The biggest advantage is the low
      cardiotoxicity.

      PEGylated doxorubicin (Caelyx®) has undergone a Phase I dose climbing clinical trial in
      children with solid tumors. The drug is safe by testing PK. The results of Phase II clinical
      studies of Caelyx® in children with progressive soft tissue sarcoma show that the drug is
      safe. Domestically produced PEGylated doxorubicin has no data on childhood tumors in China.
      Therefore, we plan to conduct a phase I study in pediatric solid tumors of pegylated
      doxorubicin combined with cyclophosphamide, vincristine, relapsed, and refractory childhood
      solid tumors. Maximum tolerated dose and effectiveness of stellate in children with solid
      tumors, thus laying the foundation for future phase II / III clinical studies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of Phase I:

      the main purpose: To evaluate the safety of PLD in combination with cyclophosphamide,
      vincristine, regenerative, and refractory solid tumors in children, including dose absorption
      toxicity (DLT)

      Secondary purpose:

        -  determine the appropriate maximum tolerated dose (MTD) and /or PLD for further clinical
           studies in this patient population;

        -  Describe the antitumor activity of PLD combined with cyclophosphamide and vincristine in
           children with advanced solid tumors or primary CNS tumors;

      Exploratory purpose:

      Effectiveness of PLD combined with cyclophosphamide and vincristine in treatment progress,
      relapse, and refractory solid tumors in children.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 21 days)</time_frame>
    <description>Maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Hematological and non-hematological toxicity (NCI CTCAE v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At the end of Cycle 2 (each cycle is 21 days)</time_frame>
    <description>Complete remission + partial remission</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Unrecognized Condition</condition>
  <arm_group>
    <arm_group_label>PLD+CTX+VCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTX 1g/m2/d，D1-2 VCR 1.5mg/m2，D1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin, cyclophosphamide, vincristine,</intervention_name>
    <description>PLD 40mg/m2 ; PLD 50mg/m2 ; PLD 60mg/m2 ; Maximum tolerated dose； Dose-limiting toxicity</description>
    <arm_group_label>PLD+CTX+VCR</arm_group_label>
    <other_name>Doxorubicin Hydrochloride Liposome Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Age: 1-18 years;

          -  2) ECOG PS score: 0-1 points;

          -  3) Patients with solid tumors confirmed by histopathology in children;

          -  4) Patients who have progressed, relapsed, or are refractory after first-line
             treatment (there is no complete or partial response after recent treatment);

          -  5) Must have at least one measurable lesion as defined by the RECIST standard;

          -  6) Expected survival time ≥ 6 months;

          -  7) Heart function:

               1. Cardiac ultrasound detection LVEF ≥ 50%;

               2. EKG indicates no myocardial ischemia;

               3. no history of arrhythmia requiring drug intervention before enrollment;

          -  8) Patients must fully recover from the acute toxic effects of all previous
             anti-cancer chemotherapy:

               1. Myelosuppressive chemotherapy: at least 21 days after the last myelosuppressive
                  chemotherapy (42 days if nitrosourea was used earlier);

               2. Experimental drugs or anti-cancer therapies other than chemotherapy: Do not use
                  within the first 28 days of the planned start of doxycycline. Full recovery from
                  the clinically significant toxicity of the therapy must be clearly identified;

               3. Hematopoietic growth factor: at least 14 days after the last dose of long-acting
                  growth factor or 3 days after the last dose of short-acting growth factor;

               4. immunotherapy: at least 42 days after completing any type of immunotherapy
                  (except steroids), such as immune checkpoint inhibitors and tumor vaccines;

               5. X-ray therapy (XRT): at least 14 days after local palliative XRT ( small range of
                  mouth); if other solid bone marrow (BM) irradiation, including prior radioactive
                  iodized meta-iodobenzidine (131I-MIBG) treatment, You must end at least 42 days;

               6. Stem cell infusion without total body irradiation (TBI): There is no evidence of
                  active graft-versus-host disease, and transplantation or stem cell infusion must
                  end at least 56 days;

          -  9) For patients who are not known to have BM:

               1. Absolute neutrophil count (ANC) ≥ 1.0 × 109 / L;

               2. Platelet count ≥100.0 × 109 / L;

               3. hemoglobin ≥90 g / L;

          -  10) Liver and kidney function should meet the following standards:

               1. Bilirubin (combined + unbound total) ≤ 2.5 × upper limit of normal value (ULN)
                  (corresponding to age), patients with Gilbert's syndrome can be enrolled
                  according to the researchers' judgment

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN;

               3. Estimated glomerular filtration rate ≥ 30 mL / min / 1.73 m2 or serum creatinine
                  (Cr) ≤ 1.5ULN;

          -  11) During the participation in the study, be able to comply with outpatient
             treatment, laboratory monitoring and necessary clinical visits;

          -  12) The parent/ guardian of the child or adolescent subject has the ability to
             understand, agree, and sign the research informed consent (ICF) and applicable child
             consent form before initiating any protocol-related procedures; subject to parent/
             guardian consent Candidates have the ability to express consent (if applicable).

        Exclusion Criteria:

          -  1) Previous or concurrent active clinical cardiovascular disease including congenital
             heart disease or pericardial disease, history of heart failure, myocardial infarction,
             coronary heart disease, heart valve disease, cardiomyopathy, arrhythmia (including
             persistent atrial fibrillation, Complete left bundle branch block, frequent
             ventricular early); or the QT interval (QTc) after the current corrected heart rate is
             extended&gt; 480 milliseconds;

          -  2) previous severe skin diseases;

          -  3) previous allergic asthma or severe allergic disease;

          -  4) Poorly controlled hypertension and diabetes;

          -  5) Have a history of other tumors, except for cured cervical cancer or skin basal cell
             carcinoma;

          -  6) Patients with hepatitis B surface antigen-positive;

          -  7) Patients infected with HIV or syphilis;

          -  8) Patients who have received organ transplants in the past;

          -  9) Uncontrolled active systemic bacterial, viral or fungal infections;

          -  10) Contraindications to high-dose hormone use, such as uncontrollable high blood
             sugar, gastric ulcer or mental illness;

          -  11) Patients who have used a total cumulative dose of doxorubicin ≥ 450 mg / m2, or a
             total cumulative dose of epirubicin ≥ 550 mg / m2, or previously used anthracyclines
             to cause heart disease;

          -  12) Have a serious neurological or psychiatric history, including epilepsy or autism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhuo Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University CancerCenter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yizhuo Zhang</last_name>
    <phone>02087342459</phone>
    <email>zhangyzh@sysucc.org.cn</email>
  </overall_contact>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/3320376</url>
    <description>Singal, P.K., C.M. Deally and L.E. Weinberg, Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol, 1987. 19(8): p. 817-28.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/496103</url>
    <description>Von Hoff, D.D., et al., Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 1979. 91(5): p. 710-7</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/12767102</url>
    <description>Swain, S.M., F.S. Whaley and M.S. Ewer, Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 2003. 97(11): p. 2869-79</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19780711</url>
    <description>Abu A L, Ishida T, Kiwada H. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.[J]. Expert Opinion on Drug Delivery, 2009, 6(12):1297.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/1737351</url>
    <description>Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes[J]. Cancer Research, 1992, 52(4):891-896.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/8932544</url>
    <description>Northfelt D W, Martin F J, Working P, et al. Doxorubicin Encapsulated in Liposomes Containing Surface-Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/14998846</url>
    <description>Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/21850390</url>
    <description>Schmitt, C.J., et al., Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Ann Hematol, 2012. 91(3): p. 391-7</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/11313175</url>
    <description>Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/11520673_Marina_NM_Cochrane_D_Harney_E_Zomorodi_K_Blaney_S_Winick_N_Bernstein_M_Link_MPDose_escalation_and_pharmacokinetics_of_pegylated_liposomal_doxorubicin_Doxil_in_children_with_solid_tumors_a_Pediatric_On</url>
    <description>Marina, N.M., et al., Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res, 2002. 8(2): p. 413-8.</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/8473195_Pegylated_liposomal_doxorubicin_hydrochloride_PLD_for_advanced_sarcomas_in_children_Preliminary_results</url>
    <description>Munoz, A., et al., Pegylated liposomal doxorubicin hydrochloride (PLD) for advanced sarcomas in children: preliminary results. Pediatr Blood Cancer, 2004. 43(2): p. 152-5.</description>
  </link>
  <reference>
    <citation>Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987 Aug;19(8):817-28. Review.</citation>
    <PMID>3320376</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710-7.</citation>
    <PMID>496103</PMID>
  </reference>
  <reference>
    <citation>Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869-79.</citation>
    <PMID>12767102</PMID>
  </reference>
  <reference>
    <citation>Abu Lila AS, Ishida T, Kiwada H. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv. 2009 Dec;6(12):1297-309. doi: 10.1517/17425240903289928. Review.</citation>
    <PMID>19780711</PMID>
  </reference>
  <reference>
    <citation>Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 1992 Feb 15;52(4):891-6.</citation>
    <PMID>1737351</PMID>
  </reference>
  <reference>
    <citation>Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996 Jan;36(1):55-63.</citation>
    <PMID>8932544</PMID>
  </reference>
  <reference>
    <citation>O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9.</citation>
    <PMID>14998846</PMID>
  </reference>
  <reference>
    <citation>Schmitt CJ, Dietrich S, Ho AD, Witzens-Harig M. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Ann Hematol. 2012 Mar;91(3):391-7. doi: 10.1007/s00277-011-1308-y. Epub 2011 Aug 18.</citation>
    <PMID>21850390</PMID>
  </reference>
  <reference>
    <citation>Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001 May;37(7):870-7.</citation>
    <PMID>11313175</PMID>
  </reference>
  <reference>
    <citation>Beverdam A, Meijlink F. Expression patterns of group-I aristaless-related genes during craniofacial and limb development. Mech Dev. 2001 Sep;107(1-2):163-7.</citation>
    <PMID>11520673</PMID>
  </reference>
  <reference>
    <citation>Wagner HE, Gilg M, Baer HU. [Characteristics of tumor diseases in patients with colorectal cancer]. Helv Chir Acta. 1993 Mar;59(4):701-3. German.</citation>
    <PMID>8473195</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yizhuo Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

